Inotropic and diuretic effects of GLP-1 and GLP-1 agonists

• US 7,442,680 B2
• Filed: 09/05/2003
• Issued: 10/28/2008
• Est. Priority Date: 02/13/1998
• Status: Expired due to Fees

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Young, Andrew A., Vine, Will, Prickett, Kathryn, Beeley, Nigel R. A.
• Primary Examiner(s): Tsang; Cecilia
• Assistant Examiner(s): BRADLEY, CHRISTINA
• Application Number:
  US10/656,093
• Publication Number:
  US 20050037958A1
• Time in Patent Office: 1,880 Days
• Field of Search: 514/2, 514/866, 530/324
• US Class Current: 514/1.1
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 38/2278 Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 13/12 of the kidneys

Abstract

Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

Claims

1. A method for treating hypertension in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a GLP-1 peptide comprising the amino acid sequence of SEQ ID NO. 3 to treat hypertension.

2. The method of claim 1, wherein the GLP-1 peptide is administered peripherally.

3. The method of claim 1, wherein the GLP-1 peptide is administered subcutaneously.

4. The method of claim 1, wherein the GLP-1 peptide is administered intravenously.

5. The method of claim 1, wherein the therapeutically effective amount is from 1 μ

g to 5 mg per dose.

6. The method of claim 1, wherein the administration is oral, buccal, pulmonary, nasal, intraocular, rectal, or transdermal.

7. A method for treating hypertension in an individual in need thereof comprising peripherally administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising a GLP-1 peptide comprising the amino acid sequence of SEQ ID NO. 3 and a pharmaceutically acceptable carrier to treat hypertension.

8. The method of claim 7, wherein the pharmaceutical composition is a slow release composition.

9. The method of claim 7, wherein the peripheral administration is subcutaneous.

10. The method of claim 7, wherein the peripheral administration is intravenous.

11. A method for treating hypertension in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a GLP-1 peptide having at least 95% sequence identity to the amino acid sequence of SEQ ID NO. 3 to treat hypertension.

13. The method of claim 11, wherein the GLP-1 peptide is administered subcutaneously.

12. The method of claim wherein the GLP-1 peptide is administered peripherally.

14. A method for treating hypertension in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a GLP-1 peptide having at least 90% sequence identity to the amino acid sequence of SEQ ID NO. 3 to treat hypertension.

15. The method of claim 14, wherein the GLP-1 peptide is administered peripherally.

16. The method of claim 14, wherein the GLP-1 peptide is administered subcutaneously.